DNLIDenali Therapeutics Inc.
$19.46+53% 1Y
$19.46
$13.0552 weeks$26.49
DNLI in its own filings
Nothing in DNLI's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
160
Events found in the filings · across 787 filings · the record starts in 2017
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 10-Q
- Record starts
- Oct 6, 2017
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- SEC comment-letter activity13 occurrences
- 2019-10-07
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights.Earnings release · press release
- Jul 28, 2026On July 27, 2026, Denali Therapeutics Inc. (the “Company”) completed the previously disclosed sale (the “Sale”) of its Rare Pediatric Disease Priority Review Voucher (the “PRV”) to a large pharmaceutical company.Acquisition or disposition completed · Form 8-K
- Jun 18, 2026On June 12, 2026, Denali Therapeutics Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Transfer Agreement”), pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”)Material agreement entered · Form 8-K
- May 7, 2026Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights.Earnings release · press release
- Apr 3, 2026On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN)Material agreement terminated · Form 8-K
- Mar 31, 2026The information contained in.New debt or off-balance-sheet obligation · Form 8-K
- Feb 26, 2026Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights.Earnings release · press release
- Dec 10, 2025On December 9, 2025, Denali Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC as representatives of the several underwriters named therein (collectively, the “Underwriters”) …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…